Children with hypoplastic lung diseases, such as congenital diaphragmatic hernia, can require life support via extracorporeal membrane oxygenation and systemic anticoagulation, usually in the form of heparin. The role of heparin in angiogenesis and organ growth is inconclusive, with conflicting data reported in the literature. This study aimed to investigate the effects of heparin on lung growth in a model of compensatory lung growth (CLG). Compared to the absence of heparin, treatment with heparin decreased the vascular endothelial growth factor (VEGF)-mediated activation of VEGFR2 and mitogenic effect on human lung microvascular endothelial cells in vitro. Compared to non-heparinized controls, heparinized mice demonstrated impaired pulmonary mechanics, decreased respiratory volumes and flows, and reduced activity levels after left pneumonectomy. They also had lower lung volume, pulmonary septal surface area and alveolar density on morphometric analyses. Lungs of heparinized mice displayed decreased phosphorylation of VEGFR2 compared to the control group, with consequential downstream reduction in markers of cellular proliferation and survival. The use of bivalirudin, an alternative anticoagulant that does not interact with VEGF, preserved lung growth and pulmonary mechanics. These results demonstrated that heparin impairs CLG by reducing VEGFR2 activation. These findings raise concern for the clinical use of heparin in the setting of organ growth or regeneration.
Introduction
Since its discovery in the early 1900s and subsequent introduction into clinical applications in the 1930s-1940s, heparin has become one of the most widely used drugs in medicine [1] and currently remains a mainstay of anticoagulation therapy [2] . Beyond its well-known role as an anticoagulant, heparin and its closely related polysaccharide, heparan sulfate (HS), exert a wide range of effects in the fields of embryology, skeletal development, inflammation, wound healing, tumor metastasis, and angiogenesis [3] [4] [5] [6] . The ability of heparin and HS to interact with major angiogenic growth factors is well-established [7] . Different forms of exogenous heparin can act as antagonists by binding and sequestering fibroblast growth factor (FGF), thus disrupting its interaction with FGFR [8] .
Vascular endothelial growth factor (VEGF), the master regulator of angiogenesis, is another growth factor that can interact with heparin due to its heparin binding domains (HBD) [9] . Analagous to its role in FGF signaling, exogenous heparin, especially at a lower molecular weight, inhibits VEGF's angiogenic effects on endothelial cells [10] . Multiple studies have discovered other heparin-like compounds that can exert similar inhibitory effects on angiogenesis in efforts to develop new anti-tumor therapies [11] [12] [13] [14] [15] .
In addition to its well-studied roles in tumor growth and metastasis, VEGF also plays a critical role in other physiologic processes, such as organ regeneration [16] .
Compensatory lung growth (CLG) after unilateral pneumonectomy is a unique process that is highly dependent on VEGF. Activation of VEGFR2 has been shown to be pivotal in CLG as mice with endothelial cell-specific Vegfr2 knockout display impaired restoration of alveolar structure and function following unilateral pneumonectomy [17] . Based on the nature of the interactions between heparin and multiple angiogenic growth factors including VEGF, we hypothesized that systemic heparinization may significantly impact physiologic processes such as organ growth and regeneration. In this study, we seek to understand the interaction between heparin and VEGF during CLG after unilateral pneumonectomy and the physiologic impact of systemic heparinization on this process.
Methods

VEGF activation and proliferation assay
For the activation assay, human microvascular lung endothelial cells (HMVEC-L) (Lonza, Morristown, NJ) were plated at 70% confluence on gelatin-coated and Matrigel®-coated plates (Corning, Corning, NY) in basal medium [EBM-2 medium (Lonza, Morristown, NJ) + 0.5% fetal bovine serum] and starved overnight at 37 °C. Cells were washed after 12 h and treated with basal medium, basal medium + 10 ng/mL VEGF 165 , or basal medium + 10 ng/ mL VEGF 165 + heparin ranging from 0 to 1 U/mL for 5 min at 37 °C. All in vitro and in vivo experiments in this study were performed with unfractionated heparin (Hospira, Lake Forest, IL). The medium was then removed and cells were quickly lysed on ice with 1× Laemmli buffer (Boston Bio Products, Ashland, MA). The supernatant was then analyzed for P-Y1175-VEGFR2 level with immunoblot.
For proliferation assay, HMVEC-L were plated at 30% confluence on gelatin and Matrigel®-coated plates in basal medium and starved overnight at 37 °C. Cells were washed after 12 h and treated with basal medium, basal medium + 10 ng/mL VEGF 165 , or basal medium + 10 ng/ mL VEGF 165 + heparin ranging from 0 to 1 U/mL. After 3 days of incubation at 37 °C, cell viability was assessed with Cell Counting Kit-8 (Dojindo Molecular Technologies, Rockville, MD) and colorimetric signal was detected with FLUOstar Omega microplate reader.
Assessment of anticoagulation functions
Eight-week old C57BL/6 male mice (Jackson Laboratories, Bar Harbor, ME) received intraperitoneal (IP) injection of normal saline at 100 µL, heparin at 500 U/kg, or bivalirudin (Sigma-Aldrich, St Louis, MO) at 50 mg/kg every 12 for 24 h and a total of three doses. One hour after the third dose of injection, blood was collected via inferior vena cava venous puncture in 9:1 ratio with trisodium citrate 3.2%. Plasma was separated by centrifugation at 3000×g for 20 min. Analysis of heparin activity on the heparinized and saline-treated control mice was performed with a chromogenic anti-factor IIa activity assay (Aniara, West Chester, OH) according to the manufacturer's protocol. Coagulation functions, including prothrombin time (PT), partial thromboplastin time (PTT), and anti-factor Xa activity, of the control and bivalirudin-treated mice were measured by the core hematology laboratory at Boston Children's Hospital.
Effects of systemic heparin on compensatory lung growth
Surgical model and experimental groups
All procedures were carried out according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee at Boston Children's Hospital. Eight-week old C57Bl/6 male mice (Jackson Laboratories, Bar Harbor, ME) were first anesthetized with ketamine 80-100 mg/kg and xylazine 10-12.5 mg/kg via IP injection and underwent left pneumonectomy as previously described [18] .
Mice were randomized into four experimental groups: control, heparin, VEGF, and VEGF + heparin. Mice in the control group received 100 µL of normal saline via IP injection immediately after surgery and daily thereafter. Mice in the heparin group were systemically heparinized as previously described [19] . Briefly, mice received IP heparin at 500 U/kg/dose immediately after surgery, followed by once every 12 h for the first 48 h after pneumonectomy and once every 24 h for the next 48 h [19] . The VEGF group received 0.5 mg/kg of recombinant murine VEGF 164 (GenScript, Piscataway, NJ) via IP injection. The heparin + VEGF group received both systemic heparinization and VEGF delivery in a similar fashion. Mice in all experimental groups were euthanized on post-operative day (POD) 4. This experimental time point was chosen based on previous work from our group, where lung growth was shown to be most active [20] .
Plethysmography and assessment of activity levels
On POD 4, mice underwent plethysmography studies (Emka Technologies, Falls Church, VA). Each mouse was placed in a sealed chamber, which measured flow and pressure changes that occur with respiration. Mice were allowed 5 min of habituation, followed by 5 min of measurement of tidal volume, expiratory volume, minute ventilation (the product of tidal volume and respiratory rate), and inspiratory and expiratory flow. Following plethysmography studies, mice were then placed in a 42 × 42 cm open field where their traveled distance and basic and fine movements were recorded for 6 min with an infrared-based motion tracking system (Motormonitor, Kinderscientific, Poway, CA). Fine movements referred to instances when the animal broke the same beam of infrared without moving from its spot, e.g., grooming or head movements, while basic movements captured the number of times the animal blocked a new beam.
Lung volume measurement
Animals were weighed and euthanized with carbon dioxide on POD 4. The remaining right lung was removed en bloc with the tracheobronchial tree. The lung was infused with formalin at 25 cmH 2 O and total lung volume was measured with the water displacement method [21] . The trachea was then ligated and the specimen was placed in 10% formalin overnight at 4 °C. All specimens were transferred into 70% ethanol after 24 h of formalin fixation and subsequently embedded in paraffin for morphometric analyses. Lung volume was normalized for body weight.
Morphometric analysis
Quantitative microscopy was performed on hematoxylin and eosin (H&E) stained lung sections based on the principles of stereology. Five lungs from each experimental group were represented by systematic uniform random sampling of 20-30 five-micron sections examined under light microscope at 200X magnification. Using a point and intersection counting technique, parenchymal volume, alveolar volume, and septal surface area were calculated [22, 23] . Parenchyma was defined as the gas-exchange compartment of the lung, which included alveoli, terminal ducts, and alveolar septa. All volume and area measurements were normalized for body weight. Alveolar density was mathematically calculated from counting the number of alveolar transections on ten randomly chosen fields at 400X magnification using the method of Weibel [24] .
Immunoblot and quantitative polymerase chain reactions (qPCR) array of VEGFR2 signaling
Fresh lung tissues from the control and heparin groups were suspended in radioimmunoprecipitation assay (RIPA) buffer (Boston Bio Products, Ashland, MA) containing protease and phosphatase inhibitors (Thermo Fisher Scientific, Waltham, MA). Tissue samples were then homogenized and centrifuged for 15 min at 4 °C and 14,000 rpm. The supernatants were collected and 40 µg of proteins were used for immunoblot. Primary antibodies included anti-P-Y1175-VEGFR2, -VEGFR2, -P-T308-Akt, -P-S473-Akt, -Akt (Cell Signaling Technology, Danvers, MA), -VEGF 120/164 (R&D Systems, Minneapolis, MN) and -β-Actin (SigmaAldrich). Secondary antibodies included horseradish-peroxidase-conjugated anti-rabbit, anti-mouse (R&D Systems) and anti-rat IgG (Jackson ImmunoResearch, West Grove, PA).
Total RNA was extracted from lung tissues with the RNeasy Mini Kit (Qiagen, Germantown, MD) according to the manufacturer's protocol. RNA concentration was determined with the NanoDrop 8000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA). Reverse transcription was performed with the RT 2 First Strand Kit (Qiagen, Germantown, MD). Synthesized cDNA was then mixed with reaction reagents provided by the RT 2 Profiler PCR Array for VEGFR2 (Qiagen, Germantown, MD). Amplification reactions were achieved with the StepOne Real-Time PCR Systems (Applied Biosystems, Foster City, CA). All target genes were normalized to the housekeeping gene β-Actin and their mRNA expression level was calculated using the 2 ΔΔC t method [25] .
Effects of bivalirudin on compensatory lung growth
Experimental groups
Mice were randomized into four experimental groups: control, bivalirudin, VEGF, and bivalirudin + VEGF. Following left pneumonectomy, mice in the control group received 100 µL of normal saline via IP injection every 12 h. Mice in the bivalirudin group were treated with IP bivalirudin at 50 mg/kg/dose every 12 h. The VEGF group received VEGF 164 at 0.5 mg/kg/dose daily and the bivalirudin + VEGF group received both bivalirudin and VEGF treatments. Mice in all experimental groups were euthanized on POD 4 and lung volume was measured as previously described.
Pulmonary mechanical studies
Pulmonary mechanical measurements with the Flexivent® system (SCIREQ, Montreal, Canada) were done on mice in the control, heparin, and bivalirudin groups immediately before euthanasia on POD 4. After anesthetization with ketamine and xylazine, a midline neck incision was made to expose the trachea, followed by tracheotomy and insertion of a 20-gauge hollow bore needle. The animal was then connected to the Flexivent® system via the tracheostomy. Dynamic elastance (lung stiffness) was measured with the single frequency forced oscillation technique, which registered the animal's response to an applied sinusoidal waveform. Total lung capacity (TLC) in this study was defined as the upper limit of the expiratory limb of the pressure-volume loop and calculated with the Salazar-Knowles equation [26] .
Statistical analyses
For in vitro assays, comparisons of VEGFR2 activation levels and cell densities among the different experimental conditions were performed with analysis of variance (ANOVA) and Holm-Sidak correction for multiple comparisons. Statistical analyses of lung volume, morphometric parameters, and pulmonary mechanical functions among the experimental groups were performed with ANOVA and Holm-Sidak correction for multiple comparisons. Comparisons of heparin activity, protein expression levels, plethysmographic measurements, and activity levels between the control and heparin groups were performed with Student's t test. For PCR array, a difference of more than twofold in gene expression between the control and heparin groups was considered significant. All analyses were performed on GraphPad Prism v7 (GraphPad Software, La Jolla, CA).
Results
Heparin reduced VEGFR2 activation in the presence of the extracellular matrix and impaired proliferation of lung endothelial cells
We first sought to examine the effects of heparin on VEGF 165 -mediated activation of VEGFR2 on HMVEC-L. Heparin treatment resulted in no difference in VEGFR2 activation when HMVEC-L were grown on gelatin-coated tissue culture plates (Fig. 1a, b) . However, on Matrigel®-coated tissue culture plates, the addition of heparin at 0.125, 0.25, 0.5, and 1 U/mL significantly impaired VEGFR2 activation compared to cells not treated with heparin (P = 0.03, 0.006, 0.001, and 0.0008, respectively) ( Fig. 1c, d ). These results suggested that the presence of the ECM modulated the effects of heparin on VEGFR2 activation. To confirm the results of activation assays, proliferation of HMVEC-L treated with 10 ng/mL of VEGF 165 was assessed after 3 days of culture in the same concentrations of heparin. Compared to VEGF 165 alone, the addition of heparin at 0.125, 0.25, 0.5, or 1 U/mL resulted in a decrease in HMVEC-L density on both gelatin-coated plates (P = 0.001, < 0.0001, < 0.0001, and < 0.0001, respectively) ( Fig. 1e) and Matrigel®-coated plates (P = 0.04, 0.01, 0.003, and 0.001, respectively) (Fig. 1f) . The anti-angiogenic effects of heparin have been reported in human umbilical vein endothelial cells (HUVEC) [27] , and a similar phenomenon was demonstrated on HMVEC-L in this study.
Systemic heparinization impaired compensatory lung growth, activity levels, and respiratory volumes after left pneumonectomy
Given the inhibitory activity of heparin on VEGFR2 activation and HMVEC-L proliferation, we speculated that systemic heparinization would impair lung growth by interfering with the interaction between VEGF and VEGFR2. To test this hypothesis, a mouse model of CLG after left pneumonectomy was used. Four experimental groups included control, heparin, VEGF, and heparin + VEGF as previously described. Systemic heparinization was first confirmed by measuring anti-factor IIa activity. Heparinized mice displayed significantly higher anti-factor IIa activity compared to control mice (0.94 ± 0.14 vs 0.32 ± 0.05 U/mL, P = 0.004) (Fig. 2a) .
Right lung volume on POD 4 was significantly lower in the heparin group compared to the control and VEGF groups (49.3 ± 1.3 vs 53.7 ± 1.0 and 59.5 ± 1.4 µL/g, P = 0.02 and < 0.0001, respectively) (Fig. 2b) . Compared to the heparin group, the combination of heparin and VEGF appeared to rescue lung growth (49.3 ± 1.3 vs 54.7 ± 1.8 µL/g, P = 0.02) but did not stimulate growth to the same volume induced by VEGF treatment alone.
Based on the evidence of impaired CLG with systemic heparinization, we next investigated the changes produced by heparin on respiratory volume and physical activity level in live animals after left pneumonectomy. On plethysmographic studies, the heparin group displayed a trend toward reduced expiratory volume compared to control mice (1.03 ± 0.06 vs 1.21 ± 0.05 µL/g, P = 0.06) (Fig. 2c) . Although not reaching statistical significance, tidal volume (P = 0.1) and minute ventilation (P = 0.1) were also lower in the heparin group (Fig. 2d, e) . The heparinized mice similarly performed worse than the control group on respiratory flow measurements, specifically peak inspiratory flow (0.58 ± 0.03 vs 0.73 ± 0.04 mL/s, P = 0.02), peak expiratory flow (0.41 ± 0.03 vs 0.52 ± 0.03 mL/s, P = 0.04), and midexpiratory flow (0.28 ± 0.02 vs 0.35 ± 0.02 mL/s, P = 0.04) (Fig. 2f-h ). On physical activity assessment, mice in the heparin group demonstrated a trend toward reduced walking distance (2.15 ± 0.09 vs 2.83 ± 0.31 × 10 3 cm, P = 0.09), basic movements (1.38 ± 0.07 vs 1.84 ± 0.18 × 10 3 , P = 0.06), and fine movements (0.73 ± 0.03 vs 0.88 ± 0.06 × 10 3 , P = 0.05) (Fig. 2i-k) . Taken together, these results demonstrated the deleterious effects of heparin on lung growth as evidenced by measurements of lung volume, activity levels, and plethysmography parameters after left pneumonectomy. (a, b) . Activation of VEGFR2 was decreased with heparin in a dose-dependent manner when HMVEC-L were grown on Matrigel®-coated plates (c, d). All experiments were done in duplicates. Heparin impaired HMVEC-L proliferation in the presence of VEGF 165 at 10 ng/mL on both gelatin and Matrigel®-coated plates in a dose-dependent manner (e, f). Cell viability was assessed with a tetrazolium assay after 3 days of incubation. All experiments were done in quadruplicates. OD: optical density. Results are expressed as mean ± SE. Kd: dissociative constant. *P ≤ 0.05; **P ≤ 0.01; ****P ≤ 0.0001 compared to heparin 0 U/mL. 
Systemic heparinization resulted in decreased alveolar regeneration on morphometric analyses
To assess changes in lung architecture, quantitative microscopy was performed using the point and intersection counting technique. Mice in the heparin group had significantly lower parenchymal volume compared to the control, VEGF, and heparin + VEGF groups (34.8 ± 2.6 vs 43.4 ± 1.8, 47.4 ± 1.1, and 42.5 ± 2.2 µL/g, P = 0.02, 0.001, and 0.02, respectively) (Fig. 3a) . Alveolar volume in the heparin group was also Fig. 2 Heparin impaired compensatory lung growth, plethysmographic measurements, and activity levels in mice after left pneumonectomy. Systemically heparinized mice had higher plasma heparin activity levels compared to control mice as assessed by anti-factor IIa activity assays (a). The heparin group displayed the lowest lung volume among the four experimental groups on post-operative day (POD) 4 (b). Compared to the control group, the heparin group demonstrated lower plethysmographic parameters, including expiratory volume (c), tidal volume (d), minute ventilation (e), peak inspiratory flow (f), peak expiratory flow (g), and mid-expiratory flow (h). Systemically heparinized mice also demonstrated reduced walking distance (i) and movement counts (j, k) on open field studies. Statistical analyses of lung volume among the experimental groups were performed with ANOVA and Holm-Sidak correction for multiple comparisons. Results are expressed as mean ± SE. *P ≤ 0.05; **P ≤ 0.01; ****P ≤ 0.0001 significantly lower than the remaining groups (20.6 ± 1.4 vs 26.7 ± 0.5, 29.6 ± 0.7, and 28.3 ± 1.9 µL/g, P = 0.004, 0.0003, and 0.001, respectively) (Fig. 3b) . Similarly, the heparin group also displayed the lowest septal surface area (14.1 ± 0.7 vs 17.2 ± 0.9, 19.0 ± 0.6, and 17.9 ± 1.0 cm 2 /g, P = 0.02, 0.002, and 0.01, respectively) (Fig. 3c) . On alveolar counting, the heparin group again demonstrated reduced alveolar density (2.63 ± 0.15 vs 3.07 ± 0.18, 4.23 ± 0.07, and 3.38 ± 0.13 × 10 7 per cm 3 , P = 0.03, P < 0.0001, and P = 0.003, respectively) (Fig. 3d) . These results, which were consistent with previous functional studies, confirmed a reduction in alveolar proliferation as a result of heparin treatment.
Systemic heparinization reduced angiogenic signaling of VEGF after left pneumonectomy
To determine the effect of systemic heparin treatment on the activation pattern of lung tissue VEGFR2, we first analyzed the protein levels of phosphorylated VEGFR2 and VEGF. We found that protein levels of VEGF 120/164 in lung tissue were significantly increased in the heparin group compared to the control group (P = 0.0007) (Fig. 4b, c) . However, the levels of VEGFR2 activation, P-Y1175-VEGFR2, were paradoxically reduced in the heparin group (P = 0.05) (Fig. 4b,  c) .
To delve deeper into the physiological implications of heparin-mediated attenuation of VEGFR2 signaling, we utilized a PCR array to analyze the expression of 84 genes implicated in angiogenesis. Compared to the control group, the heparin group displayed greater than twofold reduction in the expression of specific groups of genes associated with P-Y1175-VEGFR2 signaling pathway. These included MEK (Map2k2), MAPK (Mapk11, Mapk12, and Mapk13), and phospholipase A2 (PLA2; Pla2g12a, Pla2g2d, Pla2g3, Pla2g4a, Pla2g4b, and Pla2g5) (Fig. 4d) . Only Pik3r5, a negative regulatory subunit of phosphoinositide 3-kinase graphs at ×200 magnification of hematoxylin and eosin-stained control (e), heparin (f), VEGF (g), and heparin + VEGF (h) lung sections are shown. Results are expressed as mean ± SE. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001 Fig. 4 Heparin impaired VEGFR2 activation and reduced VEGF angiogenic signaling after left pneumonectomy in mice. VEGFR2 signaling cascade was illustrated (a). Heparin increased lung tissue levels of VEGF 120/164 but decreased activation of VEGFR2 (b, c). Polymerase chain reaction (PCR) array of VEGFR2 signaling cascade confirmed the reduction of downstream effectors such as mitogen-activated protein kinase kinase (MEK), mitogen-activated protein kinase (MAPK), phospholipase A2 (PLA2), nuclear factor of activated T-cells (NFAT), and calcineurin (d). Only Pi3kr5, which encodes a negative regulatory subunit of phosphoinositide 3-kinase (PI3K), was up-regulated. Confirmation with Western blot revealed reduction of Akt phosphorylation at residue S473 in the heparintreated mice (e, f). Results are expressed as mean ± SE. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 (PI3K), was significantly upregulated in the heparin group on PCR array (Fig. 4d) . To further investigate this finding, we also probed for the levels of phosphorylation of Akt, a downstream effector of PI3K. Compared to control lungs, heparin-treated lungs expectedly showed decreased activation of Akt, especially at the S473 residue (P = 0.03) (Fig. 4e, f) . Taken together, the results of Western blots and PCR array demonstrated a reduction in VEGFR2 activation and downstream markers of cellular proliferation and survival with systemic heparin treatment.
Bivalirudin, an alternative anticoagulant to heparin, preserved compensatory lung growth and pulmonary mechanical properties With evidence of systemic heparinization causing impaired CLG and the resulting implications on clinical practice, bivalirudin, a direct thrombin inhibitor (DTI) and alternative anticoagulant, was investigated for its effects on lung growth. Unlike heparin, bivalirudin is not known to interact with plasma proteins. First, plasma samples of saline and bivalirudin-treated mice were analyzed for coagulation functions to ensure adequate anticoagulation. Compared to control mice, bivalirudin-treated mice showed increased PT (36.7 ± 3.7 vs 10.9 ± 0.2 s, P = 0.02) and activated partial thromboplastin time (aPTT) (83.0 ± 8.6 vs 25.4 ± 2.5 s, P = 0.003) (Fig. 5a, b) . Anti-factor Xa activity, which should only be elevated with heparin treatment, was not stimulated by bivalirudin (Fig. 5c) .
Four groups of mice underwent left pneumonectomy as previously described: control, bivalirudin, VEGF, and bivalirudin + VEGF. On POD 4, there was no difference in lung volume between the bivalirudin and the control group (Fig. 5d) . The VEGF and bivalirudin + VEGF group both displayed higher lung volume compared to the control group (59.5 ± 1.1 and 60.8 ± 0.9 vs 54.6 ± 1.0 µL/g, P = 0.03 and 0.0008, respectively) (Fig. 5d) . There was no difference in lung volume between the VEGF and bivalirudin + VEGF groups.
To corroborate the results of lung volume measurements, pulmonary mechanical functions of the control, heparin, and bivalirudin groups were also determined on deeply anesthetized live animals. There was no difference in TLC between the control and bivalirudin groups. However, heparinized mice expectedly displayed reduced TLC compared to the control group (25.5 ± 0.4 vs 27.1 ± 0.5 µL/g, P = 0.04) (Fig. 5e) . Furthermore, lungs of heparinized mice showed a trend toward increased stiffness compared to the bivalirudin group (49.4 ± 2.1 vs 43.1 ± 1.5 cmH 2 O/mL, P = 0.06) (Fig. 5f ). Unlike heparin, bivalirudin, which is not known to interact with plasma proteins such as VEGF, did not impair CLG and pulmonary mechanics after left pneumonectomy.
Discussion
Heparin remains one of the most widely used therapies for anticoagulation today. Results from this study raised concern with regard to the clinical use of systemic heparin in the setting of organ regeneration. Additionally, 37% of patients on extracorporeal membrane oxygenation (ECMO) were neonates with respiratory failure according to the Extracorporeal Life Support Organization's Registry 2016 report [28] . Given the established roles of VEGF in neonatal lung development [29] [30] [31] , the use of heparin in this population could also impair lung growth via interfering with VEGF signaling.
In the present study, we first demonstrated the deleterious effects of heparin on VEGF 165 -induced activation of VEGFR2 as well as proliferation of HMVEC-L. This effect was consistent with many other previously reported studies [14, 32] . Although the effects of heparin on HMVEC-L proliferation were marginal, it should be considered in the context of VEGF stimulation. Despite resulting in a decrease of only 20% in cell density compared to no heparin, heparin at high concentrations completely neutralized the mitogenic effect of VEGF on HMVEC-L. Although there was an increase in the tissue level of VEGF 120/164 in the in vivo model, P-VEGFR2 at the Y1175 position was decreased as a result of heparin administration. Given that there was no difference in the mRNA expression of Vegfa between the two groups (data not shown), these finding indicated that heparin-mediated modulation of VEGF is post-translational and is consistent with our hypothesis of sequestration/tethering of VEGF by cell surface or ECM-bound heparin. Although the contribution of ECM in modulating the activity of VEGF in this study is speculative, indirect evidence of heparin-induced sequestration of VEGF has been shown in a human study where a single dose of heparin was sufficient to significantly decrease the serum level of VEGF after just 10 min of infusion [33] . Additionally, heparin has been demonstrated to increase the binding between VEGF 165 and the ECM [34] , which could result in sequestration of VEGF and a decrease in VEGFR2 activation as seen in this study.
We then demonstrated in an in vivo model that the administration of heparin also impaired CLG, an angiogenesis-dependent process [35, 36] . A large dose of heparin, 500 U/kg, was used in this study to mimic the state of systemic anticoagulation in the clinical setting, where heparin level is maintained between 0.3 and 0.7 U/mL. Heparinized mice displayed decreased parenchymal volume, alveolar density, and alveolar septal surface area, all of which suggest a reduced capacity for gas exchange. The findings on lung volume measurements and morphometric analyses were in fact corroborated with a series of studies aimed at assessing functional outcomes, such as pulmonary mechanical studies, plethysmographic measurements, and physical activity levels. It should also be noted that despite being systemic anticoagulated, no internal bleeding was noticed at the time of organ harvest. Additionally, microscopic examination of the lung did not reveal evidence of pulmonary hemorrhage (Fig. 3) , which could affect parameters such as lung volume and mechanics. Collectively, these results demonstrated the damaging effects of systemic heparin treatment on lung growth after left pneumonectomy.
Phosphorylation at the Y1175 position is a well-known initiating event that triggers the MAPK/ERK pathway of cellular proliferation [37] . To further confirm the effects Fig. 5 Bivalirudin did not affect compensatory lung growth and preserved pulmonary mechanical functions after left pneumonectomy. Bivalirudin, a direct thrombin inhibitor that does not interact with plasma proteins, was an effective anticoagulant in mice as demonstrated by increased prothrombin time (PT) and partial thromboplastin time (PTT) (a, b) . Anti-factor Xa activity, which is only increased with heparin treatment, was not affected by bivalirudin (c). There was no difference in lung volume on POD 4 between the bivalirudintreated and control mice (d). The combination of VEGF and bivalirudin also did not reduce the effects of VEGF on accelerating lung growth. On pulmonary mechanical studies, bivalirudin preserved total lung capacity (e) and elastance/stiffness (f) while heparinized mice performed worse on those measurements. Results are expressed as mean ± SE. *P ≤ 0.05; **P ≤ 0.01 of heparin on VEGF signal transduction, we performed a PCR array of the VEGFR2 signaling cascade. Compared to the control group, the heparin group displayed more than a twofold reduction in the expression of three main groups of downstream mediators: MAPK, PLA2, and NFAT and their activator, calcineurin. Furthermore, there was an increase in Pik3r5, a regulatory subunit of PI3K, and reduced levels of P-Akt. As Akt is a well-known pro-survival factor [38] , this finding provided further proof for the adverse effects of heparin on CLG.
Given the potential inhibitory effects of heparin on lung growth, the need for anticoagulation alternatives that are not anti-angiogenic warranted further investigation. In recent years, due to the risk of heparin-induced thrombocytopenia and heparin resistance, DTIs have emerged as a safe alternative to heparin in ECMO anticoagulation [39] . In this study, we demonstrated that systemic anticoagulation with bivalirudin, a DTI, did not result in an impairment of CLG. Although there was no statistical significance, mice anticoagulated with bivalirudin displayed slightly higher lung volume compared to the control group, and the combination of VEGF and bivalirudin may even have a synergistic effect. Anticoagulation itself may augment CLG in a fashion that is independent of VEGF. Therefore, bivalirudin and other types of anticoagulant that do not impair VEGF signaling can result in better organ growth and regeneration in patients who require systemic anticoagulation. Furthermore, the use of bivalirudin also preserved pulmonary mechanical properties. This observation therefore bears significant clinical implication and should raise concern among clinicians with regard to the use of heparin, especially in the setting of organ growth and regeneration. Bivalirudin and other DTIs therefore may present a more suitable option for anticoagulation therapy that can circumvent the anti-angiogenic effects of heparin.
